Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalbavancin Critical Pathway for ABSSSI
NCT02961764Phase 4Completed
- Sponsor
- Allergan
- Start
- Nov 2016
- Primary completion
- Mar 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dalbavancin in acute bacterial skin and skin structure infections (ABSSSI), sponsored by Allergan. Started Nov 2016; status: completed.
02
Drugs
dalbavancin
03
Conditions
acute bacterial skin and skin structure infections (ABSSSI)
Beyond the preview
Go deeper on NCT02961764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02961764.